Taiwanese journal of obstetrics & gynecology · 2025
Plateletpheresis for treating essential thrombocythemia that developed during pregnancy: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Masuko Naohisa, Tanimura Kenji, Moriuchi Koki, Kita Tomomi, Obata Kenta, Suda Sonoko, Imafuku Hitomi, Deguchi Masashi, Kurata Keiji, Yakushijin Kimikazu, Kono Keiji, Kawakatsu Takuya, Terai Yoshito
Аннотация
OBJECTIVE: Essential thrombocythemia (ET), a life-threatening disease, is associated with increased risks of hemorrhagic and thromboembolic complications. In particular, ET during pregnancy is rare and associated with an increased risk of obstetric complications. Drug therapies are frequently administered for managing pregnant women with ET, and plateletpheresis is considered to reduce platelet (PLT) counts rapidly.
CASE REPORT: A 28-year-old pregnant woman was referred to our hospital at 37 + 0/7 gestational weeks (GWs) due to severe thrombocythemia. She underwent plateletpheresis at 37 + 4/7 GWs because thrombocythemia was exacerbated. She delivered vaginally at 38 + 0/7 GWs without hemorrhagic or thromboembolic complications. She was diagnosed with ET based on a bone marrow biopsy, and ET gradually improved with medication. Thus, she and her baby were discharged without complications.
CONCLUSION: Plateletpheresis is useful for preventing hemorrhagic and thromboembolic complications at delivery in pregnant women with ET and severe thrombocythemia during the antepartum period.
CASE REPORT: A 28-year-old pregnant woman was referred to our hospital at 37 + 0/7 gestational weeks (GWs) due to severe thrombocythemia. She underwent plateletpheresis at 37 + 4/7 GWs because thrombocythemia was exacerbated. She delivered vaginally at 38 + 0/7 GWs without hemorrhagic or thromboembolic complications. She was diagnosed with ET based on a bone marrow biopsy, and ET gradually improved with medication. Thus, she and her baby were discharged without complications.
CONCLUSION: Plateletpheresis is useful for preventing hemorrhagic and thromboembolic complications at delivery in pregnant women with ET and severe thrombocythemia during the antepartum period.